MAFP (methyl-arachidonoyl-fluoro-phosphonate) is an irreversible inhibitor of cPLA2. Research has shown that this compound is also one of the most potent of the FAAH (anandamide amidohydrolase; Fatty acid amide hydrolase) inhibitors. Further studies suggest that MAFP completely blocks FAAH enzyme activity, the enzyme responsible for hydrolysis of endogenous cannabinoid ligand anandamide. Mechanistic studies suggest that this reagent specifically targets and phosphorylates arachidonyl binding sites. MAFP is an inhibitor of AChE. MAFP is an inhibitor of CB1. MAFP is an inhibitor of group VI iPLA2.
1. De Petrocellis, L., et al. 1997. Biochem. Biophys. Res. Commun. 231: 82-88. PMID: 9070224 2. Deutsch, D.G., et al. 1997. Biochem. Pharmacol. 53: 255-260. PMID: 9065728 3. Martin, B.R., et al. 2000. J. Pharmacol. Exp. Ther. 294: 1209-1218. PMID: 10945879
Soluble in methyl acetate, 100% ethanol (50 mg/ml), DMSO (50 mg/ml), DMF (~3 mg/ml), and 1:1 solution of ethanol: PES(pH7.2) (~0.5 mg/ml).
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
Martin et alMartin et al. (PubMed ID 10945879) showed MAFP s ability to manipulate endogenous cannabinoid systems by inhibiting fatty acid amidohydrolase activity (FAAH). -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn